AZN

AstraZeneca PLC (AZN) Stock Analysis: 6.2% Potential Upside Fuels Investor Interest

AstraZeneca PLC (AZN), a stalwart in the healthcare sector, continues to capture investor attention with its robust market position and promising growth potential. Headquartered in Cambridge, United Kingdom, AstraZeneca is..

AstraZeneca Plc reaches agreement with Trump administration to cut US drug prices

AstraZeneca has signed a landmark agreement with President Donald J. Trump’s administration to reduce the cost of prescription medicines for American patients...

Astrazeneca PLC (AZN)

⚠️ No article content returned.

..

AstraZeneca PLC (AZN) Stock Analysis: A Strong Buy with an 18.45% Upside Potential

AstraZeneca PLC (NASDAQ: AZN), a heavyweight in the healthcare sector, continues to capture investor attention with its robust market position and promising growth prospects. As a leading biopharmaceutical company based..

AstraZeneca PLC (AZN) Stock Analysis: Strong Buy Ratings and an 18.45% Potential Upside

AstraZeneca PLC (NASDAQ: AZN), a titan in the healthcare sector, specifically within the drug manufacturers industry, boasts a commanding presence with a market capitalization of $228.69 billion. Headquartered in Cambridge,..

AstraZeneca PLC (AZN): Investor Outlook with a 14.54% Potential Upside and Strong Buy Ratings

AstraZeneca PLC (AZN) stands prominently as a global leader in the healthcare sector, with a particular focus on the discovery, development, and commercialization of prescription medicines. With a market capitalization..

AstraZeneca’s Tezspire recommended for EU approval in chronic rhinosinusitis with nasal polyps

The European Medicines Agency’s CHMP has issued a positive opinion recommending approval of Tezspire (tezepelumab) for adult patients with chronic rhinosinusitis with nasal polyps...

AstraZeneca PLC (AZN) Stock Analysis: Exploring Growth Potential and Analyst Ratings

AstraZeneca PLC (AZN), a titan in the healthcare sector, continues to capture investor attention with its expansive portfolio in the drug manufacturing industry. With a market capitalization of $253.94 billion,..

AstraZeneca PLC (AZN) Stock Analysis: Exploring an 8.40% Upside Potential

AstraZeneca PLC (AZN), a titan in the healthcare sector, continues to capture investor attention with its robust portfolio and strategic collaborations. Known for its innovation in drug manufacturing, AstraZeneca is..

AstraZeneca PLC (AZN) Stock Analysis: Riding the 6.96% Upside Potential with Strong Buy Ratings

AstraZeneca PLC (NASDAQ: AZN), a powerhouse in the healthcare sector and a leading player in the drug manufacturing industry, stands out with its impressive market capitalization of $251.5 billion. Headquartered..

AstraZeneca PLC (AZN) Investor Outlook: Analyzing Growth Potential with a 9.40% Upside

AstraZeneca PLC (AZN), a titan in the healthcare sector, is renowned for its robust portfolio of prescription medicines that cater to a broad spectrum of medical needs. From oncology to..

AstraZeneca PLC (AZN) Stock Analysis: Exploring a 17.78% Potential Upside

AstraZeneca PLC (AZN), a leading player in the healthcare sector, continues to capture investor interest with its robust pipeline and strategic collaborations. Headquartered in Cambridge, UK, AstraZeneca specializes in the..

AstraZeneca PLC (AZN) Stock Analysis: A Robust 17.12% Potential Upside Captures Investor Attention

AstraZeneca PLC (AZN) stands as a formidable player in the healthcare sector, particularly within the drug manufacturing industry. Based in Cambridge, United Kingdom, the company boasts a substantial market capitalization..

AstraZeneca PLC (AZN): Investor Outlook Highlights Promising 18.20% Upside Potential

AstraZeneca PLC (NASDAQ: AZN), a global powerhouse in the biopharmaceutical sector, continues to capture investor attention with its robust market presence and a promising potential upside of 18.20%. As a..

AstraZeneca to invest $50bn in the US, new Virginia manufacturing site planned

AstraZeneca will invest $50bn in the United States by 2030, including a multi‑billion dollar drug substance facility in Virginia for its weight management and metabolic portfolio...

AstraZeneca PLC (AZN) Investor Outlook: Examining a 22.38% Potential Upside

AstraZeneca PLC (AZN), a titan in the healthcare sector and a leader among general drug manufacturers, presents a compelling investment opportunity. With a market capitalization of $214.36 billion, this UK-based..

AstraZeneca PLC (AZN) Stock Analysis: Exploring an 18.35% Potential Upside Amid Robust Growth Prospects

AstraZeneca PLC (AZN), a titan in the healthcare sector, continues to capture investor attention with its impressive market capitalization of $223.9 billion and promising growth trajectory. As a leading biopharmaceutical..

AstraZeneca’s Baxdrostat meets Phase III endpoints in Hypertension trial

AstraZeneca reports that baxdrostat at 1mg and 2mg doses significantly reduced mean seated systolic blood pressure at 12 weeks versus placebo in patients with uncontrolled or treatment-resistant hypertension, meeting all..

AstraZeneca PLC (AZN) Stock Analysis: Examining a Potential 21% Upside for Savvy Investors

AstraZeneca PLC (AZN), a stalwart in the global healthcare sector, remains an attractive proposition for investors, with a substantial market cap of $215.91 billion. Headquartered in Cambridge, United Kingdom, AstraZeneca..

AstraZeneca’s Imfinzi approved in EU for muscle-invasive bladder cancer

AstraZeneca’s Imfinzi (durvalumab) has been approved in the EU for use alongside chemotherapy before, and as monotherapy after, bladder removal surgery in adults with resectable muscle-invasive bladder cancer...
Search

Funds

AZN

AstraZeneca Plc reaches agreement with Trump administration to cut US drug prices

AstraZeneca has signed a landmark agreement with President Donald J. Trump’s administration to reduce the cost of prescription medicines for American patients...

AstraZeneca’s Tezspire recommended for EU approval in chronic rhinosinusitis with nasal polyps

The European Medicines Agency’s CHMP has issued a positive opinion recommending approval of Tezspire (tezepelumab) for adult patients with chronic rhinosinusitis with nasal polyps...

AstraZeneca to invest $50bn in the US, new Virginia manufacturing site planned

AstraZeneca will invest $50bn in the United States by 2030, including a multi‑billion dollar drug substance facility in Virginia for its weight management and metabolic portfolio...

AstraZeneca’s Baxdrostat meets Phase III endpoints in Hypertension trial

AstraZeneca reports that baxdrostat at 1mg and 2mg doses significantly reduced mean seated systolic blood pressure at 12 weeks versus placebo in patients with uncontrolled or treatment-resistant hypertension, meeting all primary and secondary endpoints, with a favourable safety profile...

AstraZeneca’s Imfinzi approved in EU for muscle-invasive bladder cancer

AstraZeneca’s Imfinzi (durvalumab) has been approved in the EU for use alongside chemotherapy before, and as monotherapy after, bladder removal surgery in adults with resectable muscle-invasive bladder cancer...
Search

Funds

AZN

FTSE 100

Funds